Ondansetron Reverses Antihypersensitivity from Clonidine in Rats after Peripheral Nerve Injury: Role of γ-Aminobutyric Acid in α2-Adrenoceptor and 5-HT3 Serotonin Receptor Analgesia
Hayashida, Ken-ichiro D.V.M., Ph.D.*; Kimura, Masafumi M.D.†; Yoshizumi, Masaru Ph.D.‡; Hobo, Shotaro M.D.‡; Obata, Hideaki M.D., Ph.D.§; Eisenach, James C. M.D.‖
Introduction: Monoaminergic pathways, impinging an α2-adrenoceptors and 5-HT3 serotonin receptors, modulate nociceptive transmission, but their mechanisms and interactions after neuropathic injury are unknown. Here we examine these interactions in rodents after nerve injury.
Methods: Male Sprague-Dawley rats following L5–L6 spinal nerve ligation (SNL) were used for either behavioral testing, in vivo microdialysis for γ-aminobutyric acid (GABA) and acetylcholine release, or synaptosome preparation for GABA release.
Results: Intrathecal administration of the α2-adrenoceptor agonist (clonidine) and 5-HT3 receptor agonist (chlorophenylbiguanide) reduced hypersensitivity in SNL rats via GABA receptor-mediated mechanisms. Clonidine increased GABA and acetylcholine release in vivo in the spinal cord of SNL rats but not in normal rats. Clonidine-induced spinal GABA release in SNL rats was blocked by α2-adrenergic and nicotinic cholinergic antagonists. The 5-HT3 receptor antagonist ondansetron decreased and chlorophenylbiguanide increased spinal GABA release in both normal and SNL rats. In synaptosomes from the spinal dorsal horn of SNL rats, presynaptic GABA release was increased by nicotinic agonists and decreased by muscarinic and α2-adrenergic agonists. Spinally administered ondansetron significantly reduced clonidine-induced antihypersensitivity and spinal GABA release in SNL rats.
Conclusion: These results suggest that spinal GABA contributes to antihypersensitivity from intrathecal α2-adrenergic and 5-HT3 receptor agonists in the neuropathic pain state, that cholinergic neuroplasticity after nerve injury is critical for α2-adrenoceptor-mediated GABA release, and that blockade of spinal 5-HT3 receptors reduces α2-adrenoceptor-mediated antihypersensitivity via reducing total GABA release.
What We Already Know about This Topic
* Descending noradrenergic and serotonergic pathways inhibit nociceptive transmission in the spinal cord
* The action is mediated through α1-adrenoceptors on γ-aminobutyric acid (GABA) interneurons
What This Article Tells Us That Is New
* Following spinal nerve ligation, spinal GABA contributes to the antihypersensitivity effects mediated by α2 and serotonin receptors
* In this model, the effects of α2 adrenoceptors on GABA release is mediated, in part, by enhanced acetylcholine release
* Blockade of spinal serotonin receptors reduces basal GABA tone and decreases α2 receptor mediated antihypersensitivity
NEARLY 50 yr ago, Melzack and Wall proposed a theory of pain transmission wherein activity of touch-sensitive afferents could inhibit transmission by nociceptive afferents at the spinal level.1
They further speculated that this gate control was powerfully regulated by pathways descending from higher centers. In the 1970s, two monoamine pathways, one releasing noradrenaline and another releasing serotonin, were identified as inhibitory of nociceptive neurotransmission.2
The purpose of this study was to address key gaps in our understanding about the role of these pathways after neuropathic injury and their mechanisms of action. We focused on their regulation of γ-aminobutyric acid (GABA), a key inhibitory neurotransmitter of projecting neurons in the spinal cord.
Noradrenaline is released by bulbospinal noradrenergic axons originating from the locus coeruleus and adjacent nuclei in the brainstem,3
and suppresses pain transmission via
inhibitory α2-adrenoceptors on sensory terminals and projecting neurons, and via
excitatory α1-adrenoceptors on GABA interneurons.2
Although noradrenergic inhibition exists in the normal state, peripheral nerve injury induces drastic changes in anatomy and function of this pathway. Peripheral nerve injury results in an increase in noradrenergic axon density in the spinal cord and induces more noradrenaline release when this pathway is stimulated.5
In synaptosomes prepared from the lumbar dorsal horn, activation of α2-adrenoceptors, which inhibits acetylcholine release in the normal state, facilitates acetylcholine release after peripheral nerve injury via
G protein-mediated mechanisms.7
This facilitation of spinal acetylcholine release after nerve injury is critical for analgesia from intrathecal injection of α2-adrenoceptor agonists such as clonidine.9
In the normal state, stimulation of nicotinic and muscarinic receptors on GABA neurons increases GABA release to inhibit pain transmission in the spinal cord.11–17
In the neuropathic pain state, however, the roles of α2-adrenergic and cholinergic receptors on spinal GABA release are not known. We hypothesized that α2-adrenoceptor-mediated analgesia after nerve injury depends on cholinergic mediated GABA release.
Spinal serotonin is released from descending serotonergic axons that originate from the rostral ventral medulla,18
and has both inhibitory or facilitatory effects on pain transmission in the spinal cord.2
Spinal administration of the 5-hydroxytryptophan-3 (5-HT3) receptor antagonist ondansetron inhibits pain-related behaviors and activity of spinal neurons in rats following peripheral formalin injection,19
suggesting a facilitatory role of endogenous serotonin in spinal pain transmission via
5-HT3 receptors. After nerve injury, however, the role of 5-HT3 receptors is less clear, because the antagonist ondansetron has inconsistent effects21
and the 5-HT3 receptor selective agonist chlorophenylbiguanide (m-CPBG) reduced hypersensitivity.23
The behavioral effect of m-CPBG after nerve injury is blocked by GABA antagonists,23
and 5-HT3 agonists induce presynaptic GABA release in normal rats,24
suggesting a role for GABA in its action. We hypothesized that m-CPBG would increase and ondansetron would decrease spinal GABA release in both normal and spinal nerve ligation (SNL) rats. Finally, because intrathecal clonidine produces analgesia in patients with neuropathic pain and because some studies suggest that ondansetron should also be analgesic, we examine the behavioral effects of this combination. Surprisingly, we observed antagonism of clonidine's effect by ondansetron, and tested whether this could be explained by opposing actions on GABA release.
Materials and Methods
Animals and Surgeries
Male Sprague-Dawley rats (weighing 180–250 g) from Harlan Industries (Indianapolis, IN) and Japan SLC Inc. (Hamamatsu, Japan), housed under a 12-h light-dark cycle with food and water ad libitum, were used. All experiments were approved by Animal Care and Use Committee at Wake Forest University (Winston Salem, NC) and Gunma University (Maebashi, Japan). Microdialysis study for acetylcholine release was performed at Gunma University and other experiments were performed at Wake Forest university.
L5–L6 spinal nerve ligation was performed as previously described.26
Briefly, animals were anesthetized with 2% isoflurane in oxygen and the right L5 and L6 spinal nerves were tightly ligated with 5–0 silk sutures. One week after SNL, intrathecal catheterization was performed as previously described.27
Briefly, animals were anesthetized with 2 or 3% isoflurane. A small puncture was made in the atlantooccipital membrane of the cisterna magnum and a polyethylene catheter (ReCathCO LLC, Allison Park, PA), 7.5 cm, was inserted. After surgery, animals were allowed to recover for a week.
In SNL animals, paw withdrawal threshold in response to light touch with calibrated von Frey filaments (Stoelting, Wood Dale, IL) was determined using an up-down statistical method.28
Filaments were applied to the bending point for 5 s, and a brisk paw withdrawal was considered a positive response.
In normal animals, withdrawal threshold to pressure applied to the hind paw, expressed in grams, was measured using an analgesimeter (Ugo Basile, Comerio, Italy), as previously described.29
The device applies increasing pressure to the hind paw. When the animal withdrew the paw or vocalized, the pressure was immediately released and the withdrawal threshold read on a scale. Training of animals for this test was performed for 3–5 days before the drug treatment. A cutoff of 250 g was used to avoid potential tissue injury. Withdrawal threshold was measured two times in the right and left hind paws, and these values were averaged for each animal.
On the day of the experiment, animals received an intrathecal injection of test drug at a volume of 10 μl followed by 10 μl saline. We used these normal and SNL animals two or three times on different days. Experiments in the same animals were separated by at least 5 days. Drugs and their doses were randomly assigned. The person performing the behavioral test was blinded to drug and treatment.
Animals were anesthetized with 2% isoflurane and then maintained with 1.25 to 1.5% isoflurane during the study. A heating blanket was used to maintain rectal temperature (36.5 ± 0.5°C) and the right jugular vein was cannulated for saline infusion (1.2 ml · kg−1 · h−1). The L3–L6 level of spinal cord was exposed by the T13-L1 laminectomy. A microdialysis probe (OD = 0.22 mm, ID = 0.20 mm, length = 1 mm; CX-I-8–01; EICOM, Kyoto, Japan) was inserted from just lateral to the right dorsal root 1 h before the study and perfused with Ringer's solution. Fractions were collected every 30 min for 2.5 h, starting 1 h before drug treatment, and samples were kept at −80°C until assay for GABA. GABA content in the microdialysates was measured by a high-pressure liquid chromatography system with electrochemical detection (HTEC-500, EICOM). GABA in samples were derivatized with 2-mercaptoethanol and ο-phthaldialdehyde (4 mM) in 0.1 M carbonate buffer (pH = 9.5). The ο-phthaldialdehyde derivatives were then separated on the column (3.0 mm × 150 mm, SC-5ODS, EICOM) at 30°C, using a mobile phase consisting of 50 mM phosphate buffer (pH = 2.8) and methanol (1:1 vol/vol) containing 5 mg/ml EDTA-2Na at a flow rate of 0.5 ml/min. The limit of detection of GABA assay in the current study was 1.5 pg per injection (15 μl) and the interassay coefficient of variation at 100 pg per injection was 7.2%.
Anesthesia was induced with urethane (1.2 to 1.5 g/kg, intraperitoneal) and then maintained with 0.5% isoflurane. The left femoral vein was cannulated for saline infusion, rectal temperature was maintained at 36.5 ± 0.5°C, and the L3–L6 level of spinal cord was exposed. A microdialysis probe (OD = 0.22 mm, ID = 0.20 mm, length = 2 mm; AI8-02; EICOM) was inserted from just lateral to the dorsal root and advanced at a 30° angle to a depth of 2 mm and perfused with Ringer's solution (1.0 μl/min). After 120 min of constant perfusion, fractions were collected into a sample-injector (EAS-20; EICOM) connected with HTEC-500 analyzing system every 30 min for 2.5 h, starting 1 h before drug treatment. The sample was then separated on the column (2.0 mm × 150 mm; EICOMPAC AC-GEL; EICOM) at 33°C, using a mobile phase consisted of 50 mM carbonate buffer containing 300 mg/l sodium decane-1-sulfonate (pH = 8.5) and 50 mg/l EDTA-2Na at a flow rate of 0.15 ml/min. The limit of detection of acetylcholine assay in the current study was 10 fg per injection (30 μl) and the interassay coefficient of variation at 30 pg per injection was 8.2%.
GABA Release from Synaptosomes
Crude synaptosomes from the lumbar spinal dorsal horn ipsilateral to SNL surgery were prepared, as previously described.7
Under deep anesthesia with 5% isoflurane, animals were killed by decapitation and the spinal lumbar enlargement was quickly removed and placed in ice-cold sucrose (0.32 M)-HEPES (10 mM) buffer, pH = 7.4. Each synaptosome preparation contained unilateral dorsal quadrants of spinal cord from three SNL rats. The initial homogenate was centrifuged at 1,000 x G for 3 min and the resulting supernatant was centrifuged again at 10,000 x G for 13 min. The supernatant was discarded and the pellet was resuspended in Krebs buffer (in mM: NaCl 124, KCl 3, MgSO4
25, and glucose 10, saturated with 95% O2
, pH = 7.4). [3
H]-GABA release from synaptosomes was measured as previously described,30
with minor modifications. After incubation with [3
H]-GABA and unlabeled GABA (final concentration of 0.25 μCi/ml and 1 μM, respectively) for 20 min at 37°C, the synaptosome-containing solution was centrifuged at 10,000 x G for 5 min and the pellet was resuspended in Krebs buffer. Each synaptosome preparation was divided into six equal aliquots and transferred to Whatman filters in individual temperature controlled perfusion chambers (SF-12; Brandel, Gaithersburg, MD). Synaptosomes were perfused with Krebs buffer (0.8 ml/min) for 25 min to remove free radioactivity, and then fractions were collected every 5 min for 20 min. After a 10 min baseline collection, synaptosomes were stimulated with 12 mM KCl-Krebs buffer (in mM: NaCl 115, KCl 12, MgSO4
25, and glucose 10, pH = 7.4) containing test drug for 3 min. In a separate experiment, synaptosomes were perfused with ondansetron for 2 min and then stimulated with 12 mM KCl-Krebs buffer containing nicotine with ondansetron for 3 min. The inhibitor of GABA transporters 1,2,5,6-tetrahydro-1-[2-[[(diphenylmethylene)amino]oxy]ethyl]-3-pyridinecarboxylic acid hydrochloride (1 μM NNC-711; Tocris Bioscience, Ellisville, MO) was present during perfusion to inhibit reuptake of GABA.30
Amount of radioactivity of each fraction was measured by a liquid scintillation spectrometry (LS6500; Beckman Coulter Inc., Fullerton, CA).
Clonidine hydrochloride, ondansetron hydrochloride, dolasetron mesylate, bicuculline methiodide, atropine sulfate, mecamylamine hydrochloride, idazoxan hydrochloride, (−)-nicotine, epibatidine dihydrochloride, and muscarine chloride were obtained from Sigma-Aldrich (St. Louis, MO). Dexmedetomidine hydrochloride, 3-Aminopropyl-diethoxymethyl phosphinic acid hydrate (CGP 35348), and 1-(3-Chlorophenyl)-biguanide hydrochloride (mCPBG) were obtained from Tocris Bioscience. Each drug was dissolved in saline, Ringer's solution, or Krebs buffer. A higher concentration of ondansetron was used in microdialysis than in synaptosome experiments, because of barriers of drug diffusion in the former.
Unless otherwise stated, data are presented as mean ± SE. Behavioral and microdialysis data were analyzed using one-way or two-way repeated measures ANOVA followed by Tukey post hoc test. Synaptosome data were analyzed by one-way ANOVA followed by Dunnet post hoc test. P < 0.05 was considered significant.
Spinal GABA Contributes to α-2 Adrenoceptor-mediated Antihypersensitivity
SNL strongly reduced the withdrawal threshold in the paw ipsilateral to surgery from 16.7 ± 4.3 g to 1.8 ± 1.0 g (mean ± SD, n = 165, P
< 0.0001) at 2 weeks after surgery. Intrathecal injection of clonidine (15 μg/rat) increased withdrawal threshold in the paw ipsilateral to SNL compared with saline in a time-dependent manner (fig. 1
< 0.05). This clonidine effect was significantly reduced by the GABAA
receptor antagonist bicuculline (0.25 μg/rat) but not by the GABAB
antagonist CGP 35348 (15 μg/rat) at 60 min after injection. Neither GABA antagonist alone affected withdrawal threshold in SNL rats. The doses of bicuculline and CGP35348 were determined from a previous study.23
Consistent with previous observations in rats after peripheral nerve or spinal cord injury,31–33
baseline concentrations of GABA in microdialysates from the spinal dorsal horn were significantly less from SNL rats (36.8 ± 3.3 pg/30 μl, n = 89) compared with normal rats (76.8 ± 9.7 pg/30 μl, n = 38, P
< 0.001). Clonidine did not affect GABA concentrations in microdialysates from the spinal dorsal horn in normal rats but increased them in SNL rats (fig. 1
B). This clonidine-induced GABA release in SNL rats peaked at 100 μM clonidine in the perfusate and decreased at 300 μM clonidine. At 100 μM clonidine, the GABA concentrations in the dialysates from the SNL spinal cord increased within 30 min, peaked at 60 min, and decreased at 90 min. Based on this result, we selected 100 μM clonidine for the following experiments. Neither α2-adrenoceptor antagonist idazoxan (300 μM), muscarinic antagonist atropine (100 μM), nor nicotinic antagonist mecamylamine (100 μM), affected GABA concentrations in microdialysates from the spinal dorsal horn of SNL rats (fig. 2
A). Coperfusion of mecamylamine or idazoxan with clonidine significantly reduced clonidine-induced GABA release at 60–90 min in the spinal dorsal horn of SNL rats (P
< 0.05). On the other hand, atropine significantly enhanced clonidine-induced GABA release at 60–90 min in the spinal dorsal horn of SNL rats (P
The roles of cholinergic and α2-adrenergic receptors on presynaptic GABA release were examined in synaptosomes prepared from the lumbar spinal dorsal horn of SNL rats. Basal or 12 mM KCl-evoked GABA release in the synaptosomes from SNL rats was increased by the nicotinic agonists, epibatidine and nicotine, but decreased by muscarine in a concentration-dependent manner (fig. 2
B). In contrast to the microdialysis results from spinal cord in vivo
with intact circuits, stimulation of α2-adrenoceptors in isolated GABA terminals by the highly selective agonist dexmedetomidine (10 nM) significantly reduced basal and KCl-evoked GABA release in SNL rats.
Baseline concentrations of acetylcholine in microdialysates from the spinal dorsal horn did not differ between normal (4.7 ± 0.7 pg/30 μl, n = 13) and SNL (4.5 ± 0.71 pg/30 μl, n = 13) rats. Similar to the GABA microdialysis results, clonidine increased spinal acetylcholine release in SNL rats but not in normal rats (fig. 3
). The acetylcholine concentrations in the dialysates from the SNL spinal cord increased within 30 min, peaked at 60 min, and decreased at 90 min during clonidine perfusion.
Spinal GABA Contributes to 5-HT3 Receptor-mediated Antihypersensitivity
As previously reported,23
intrathecal injection of mCPBG (15 μg/rat) in SNL rats produced an antihypersensitivity effect that was blocked by bicuculline and CGP 35348 (fig. 4
We then examined effects of blockade or stimulation of 5-HT3 receptors on spinal GABA release in normal and SNL rats. Ondansetron (100 μM) reduced but mCPBG (100 μM) increased GABA concentrations in microdialysates from the spinal dorsal horn in both normal and SNL rats in time-dependent manners (fig. 4
Blockade of 5-HT3 Receptors Reduces Clonidine-induced GABA Release and Antihypersensitivity in SNL Rats
In SNL rats, an intrathecal injection of ondansetron (10 μg/rat) alone slightly but significantly increased withdrawal threshold in the paw ipsilateral to surgery compared with saline (fig. 5
< 0.05). The antihypersensitivity effect of intrathecal clonidine (15 μg/rat) was partially reduced by ondansetron (0.3–30 μg/rat) in a dose-dependent manner. Another selective 5-HT3 receptor antagonist dolasetron (100 μg/rat) itself produced minor antihypersensitivity and also reduced clonidine's effect in SNL rats. The dose of dolasetron was determined from our previous study.22
In normal rats, intrathecal injection of clonidine (3–30 μg/rat) dose-dependently increased withdrawal threshold (fig. 5
B). Ondansetron (3–30 μg/rat) failed to affect withdrawal threshold and clonidine-induced antinociception in normal rats, in contrast to its inhibition of clonidine's effect after SNL.
In the spinal dorsal horn of SNL rats, coperfusion of ondansetron with clonidine significantly increased GABA concentrations in microdialysates compared with ondansetron alone and decreased them compared with clonidine alone (fig. 6
Because nicotinic receptors are involved in clonidine-induced spinal GABA release in SNL rats, we lastly examined whether ondansetron affects nicotine-induced GABA presynaptic GABA release. In the spinal dorsal horn synaptosomes from SNL rats, ondansetron (1–10 μM) did not affect nicotine-induced GABA release (fig. 6
Descending serotonergic and noradrenergic pathways act on multiple targets to reduce and, in some circumstances, enhance excitation of primary sensory afferents and second-order neurons in the spinal cord.2
The current study demonstrated, in rats after peripheral nerve injury, that some inhibitory actions of both pathways rely in part on spinal GABA for their behavioral antihypersensitivity effects and that α2-adrenoceptors require cholinergic neuronal plasticity following nerve injury to induce GABA release in the spinal dorsal horn. They also predict an adverse, antagonistic effect from ondansetron in patients receiving intrathecal clonidine for analgesia for neuropathic pain.
In both normal and neuropathic pain states, activation of α2-adrenoceptors reduces presynaptic release of pronociceptive neurotransmitters including substance P and glutamate from primary afferent and hyperpolarizes spinal neurons via
activation of potassium channels subsequent to stimulation of Gi/o-proteins, as key mechanisms of antinociception.2
In addition to these mechanisms, the current study suggests that α2-adrenoceptors also reduce hypersensitivity after nerve injury by increasing GABA release. This is not a direct effect, but requires spinal cord circuits, since it was present in vivo
in the microdialysis experiments but not in vitro
in studies in isolated synaptosomes. Clonidine-induced GABA release in the spinal cord in vivo
relies on acetylcholine release, because it was blocked by mecamylamine. These results are consistent with novel Gs-mediated facilitation of acetylcholine release from α2-adrenoceptor stimulation in the spinal dorsal horn after peripheral nerve injury.7
This novel excitatory action, previously demonstrated in vitro
, is extended in the current study in vivo
, using microdialysis. Together, these results suggest that stimulation of α2-adrenoceptors on cholinergic terminals results in acetylcholine release, which in turn induces GABA release to reduce hypersensitivity after nerve injury. These data further extend our understanding of the α2-adrenoceptors and nicotinic and GABA receptors in analgesia. Taken together, they suggest that potency and efficacy of intrathecal clonidine is enhanced in neuropathic states because of novel cholinergic excitation (fig. 7
, top panels). A limitation of the study design, which compared nerve-injured animals and tissues with normal ones, was that we could not distinguish the effect of surgery and nerve injury compared with normal from the effect of a surgical procedure without nerve injury.
Stimulation of nicotinic receptors in the spinal cord causes presynaptic GABA release and GABAA
receptor-mediated analgesia in both normal and nerve-injured rats,13
consistent with the current behavioral and neurochemical observations. These results suggest that γ-aminobutyric acid-mediated, or GABAergic, mechanisms contribute to nicotinic receptor-mediated antihypersensitivity from intrathecal clonidine in SNL rats. In contrast, the GABAB
antagonist CGP35348, at a dose which abolished antihypersensitivity from mCPBG, failed to affect antihypersensitivity from clonidine in SNL rats. Because both α2-adrenoceptors and GABAB
receptors are expressed on primary sensory afferents and their stimulation reduces pronociceptive neurotransmitter release,2
activation of α2-adrenoceptors by clonidine might mask the effect of CGP35348.
We have previously demonstrated that peripheral nerve injury up-regulates inhibitory M2 muscarinic receptors in primary sensory afferents.37
Stimulation of M2 muscarinic receptors reduces pain-related behavior following formalin injection in rats, and inhibits heat- or capsaicin-evoked release of calcitonin gene-related peptide from primary sensory neurons.38
Stimulation of M2, M3, and M4 subtype of muscarinic receptors also results in presynaptic GABA release in the spinal cord and GABAB
receptor-mediated analgesia in normal rats or those with diabetic neuropathy.11
However, the current study in SNL rats demonstrated that atropine enhanced clonidine-induced GABA release in the spinal dorsal horn and muscarine reduced presynaptic GABA release from the synaptosome. Although we did not examine which subtype(s) of muscarinic receptors contribute to the inhibition of GABA release and whether peripheral nerve injury alters the function or expression of muscarinic receptors on GABA neurons in the spinal dorsal horn, these results suggest that muscarinic receptors have an inhibitory role on GABA neurons in the spinal cord after peripheral nerve injury and that GABAergic mechanisms are less likely to contribute to muscarinic receptor-mediated antihypersensitivity from clonidine after nerve injury.
Stimulation of 5-HT3 receptors in the spinal cord can result in facilitation of pain transmission via
increasing substance P release from the primary sensory afferents40
or inhibition by increasing GABA release.24
A facilitation of pain from the tonic activity of spinal 5-HT3 receptors has been described in several persistent pain states. As such, intrathecal injection of ondansetron in rats20
or genetic deletion of 5-HT3 receptors in mice42
reduced pain-related behavior following the formalin injection into the paw. Single or repeated intrathecal injection of ondansetron reduced mechanical hypersensitivity in rats after spinal cord or peripheral nerve injury.21
Paradoxically, 5-HT3 receptor agonists also reduce hypersensitivity in the same pain states where endogenous serotonin induces 5-HT3 receptor-mediated facilitation. As such, intrathecal administration of the 5-HT3 agonists resulted in reduction of formalin-evoked behavior in normal rats45
and GABA receptor-dependent antihypersensitivity in SNL rats.23
The current study confirmed both facilitatory and inhibitory roles of 5-HT3 receptors in the spinal dorsal horn in SNL rats. For the former, intrathecal injection of 5-HT3 receptor antagonists produced a small but significant antihypersensitivity. For the latter, spinally administered mCPBG increased GABA release in the spinal dorsal horn and produced GABA receptor-dependent antihypersensitivity. The current study also demonstrated that the spinally administered ondansetron reduced spinal GABA release in normal and SNL rats, consistent with a tonic 5-HT3 receptor-dependent enhancement of GABA release. Taken together, these results suggest that stimulation of 5-HT3 receptors results in activation of both facilitatory and inhibitory pathways in the spinal cord and that behavioral consequence of spinal 5-HT3 receptor activation in animals after nerve injury may depend on the balance between these pathways (fig. 7
, lower panels).
Based on the previously described analgesic effects of clonidine and ondansetron in various pain states, we originally hypothesized that combination of α2-adrenoceptor stimulation with blockade of 5-HT3 receptors in the spinal cord should produce additive or synergistic antihypersensitivity in SNL rats. Contrary to this hypothesis, ondansetron partially antagonized rather than enhanced antihypersensitivity from intrathecal clonidine in SNL rats, consistent with a reduction of clonidine-induced GABA release by ondansetron in the spinal cord. This is unlikely because of a direct interaction on α2-adrenoceptors by ondansetron because, to our knowledge, there is no evidence that this drug binds to these receptors. Because ondansetron did not affect nicotine-induced presynaptic GABA release from synaptosomes in SNL rats, this inhibitory effect of ondansetron on GABA release is not likely because of the direct inhibition of nicotinic receptors that mediate GABA release by clonidine. On the other hand, ondansetron did not affect antinociception from intrathecal clonidine in normal rats in which clonidine does not induce spinal GABA release. These results suggest that facilitatory influence of tonic 5-HT3 receptor activity on basal GABA tone in the spinal cord after nerve injury is important for α2-adrenoceptor-mediated antihypersensitivity, which relies on spinal GABA release.
In summary, stimulation of α2-adrenergic and 5-HT3 receptors results in spinal GABA release and GABA receptor-mediated antihypersensitivity in rats after peripheral nerve injury, and cholinergic neuroplasticity after nerve injury is critical for the GABA release from α2-adrenoceptor activation in the spinal dorsal horn. These results suggest that spinal α2-adrenergic and 5-HT3 pathways share a common mechanism to reduce neuropathic pain after nerve injury. The current study also demonstrates that blockade of spinal 5-HT3 receptors reduces α2-adrenoceptor-mediated antihypersensitivity in SNL rats via
reduction of basal GABA tone in the spinal cord. Because 5-HT3 receptor antagonists are commonly used for the treatment of nausea and vomiting46
and because orally administered ondansetron crosses the blood-brain barrier,47
clinical trials in chronic pain patients should be performed to test whether 5-HT3 receptor antagonists affect efficacy of analgesics that rely on spinal α2-adrenoceptor action, including intrathecal clonidine and oral gabapentin.48
1. Melzack R, Wall PD: Pain mechanisms: A new theory. Science 1965; 150:971–9
2. Millan MJ: Descending control of pain. Prog Neurobiol 2002; 66:355–474
3. Aston-Jones G, Shipley MT, Chouvet G, Ennis M, van Bockstaele E, Pieribone V, Shiekhattar R, Akaoka H, Drolet G, Astier B, Charléty P, Valentino RJ, Williams JT: Afferent regulation of locus coeruleus neurons: Anatomy, physiology and pharmacology. Prog Brain Res 1991; 88:47–75
4. Pertovaara A: Noradrenergic pain modulation. Prog Neurobiol 2006; 80:53–83
5. Hayashida K, Obata H, Nakajima K, Eisenach JC: Gabapentin acts within the locus coeruleus to alleviate neuropathic pain. ANESTHESIOLOGY 2008; 109:1077–84
6. Hayashida K, Clayton BA, Johnson JE, Eisenach JC: Brain derived nerve growth factor induces spinal noradrenergic fiber sprouting and enhances clonidine analgesia following nerve injury in rats. Pain 2008; 136:348–55
7. Hayashida K, Eisenach JC: Spinal alpha 2-adrenoceptor-mediated analgesia in neuropathic pain reflects brain-derived nerve growth factor and changes in spinal cholinergic neuronal function. ANESTHESIOLOGY 2010; 113:406–12
8. Hayashida K, Eisenach JC: A tropomyosine receptor kinase inhibitor blocks spinal neuroplasticity essential for the anti-hypersensitivity effects of gabapentin and clonidine in rats with peripheral nerve injury. J Pain 2010; 12:94–100
9. Pan HL, Chen SR, Eisenach JC: Intrathecal clonidine alleviates allodynia in neuropathic rats: Interaction with spinal muscarinic and nicotinic receptors. ANESTHESIOLOGY 1999; 90:509–14
10. Paqueron X, Conklin D, Eisenach JC: Plasticity in action of intrathecal clonidine to mechanical but not thermal nociception after peripheral nerve injury. ANESTHESIOLOGY 2003; 99:199–204
11. Baba H, Kohno T, Okamoto M, Goldstein PA, Shimoji K, Yoshimura M: Muscarinic facilitation of GABA release in substantia gelatinosa of the rat spinal dorsal horn. J Physiol 1998; 508(Pt 1):83–93
12. Chen SR, Pan HL: Spinal GABAB receptors mediate antinociceptive actions of cholinergic agents in normal and diabetic rats. Brain Res 2003; 965:67–74
13. Genzen JR, McGehee DS: Nicotinic modulation of GABAergic synaptic transmission in the spinal cord dorsal horn. Brain Res 2005; 1031:229–37
14. Pan HL, Wu ZZ, Zhou HY, Chen SR, Zhang HM, Li DP: Modulation of pain transmission by G-protein-coupled receptors. Pharmacol Ther 2008; 117:141–61
15. Rashid MH, Ueda H: Neuropathy-specific analgesic action of intrathecal nicotinic agonists and its spinal GABA-mediated mechanism. Brain Res 2002; 953:53–62
16. Zhang HM, Chen SR, Cai YQ, Richardson TE, Driver LC, Lopez-Berestein G, Pan HL: Signaling mechanisms mediating muscarinic enhancement of GABAergic synaptic transmission in the spinal cord. Neuroscience 2009; 158:1577–88
17. Zhang HM, Li DP, Chen SR, Pan HL: M2, M3, and M4 receptor subtypes contribute to muscarinic potentiation of GABAergic inputs to spinal dorsal horn neurons. J Pharmacol Exp Ther 2005; 313:697–704
18. Steinbusch HW: Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals. Neuroscience 1981; 6:557–618
19. Green GM, Scarth J, Dickenson A: An excitatory role for 5-HT in spinal inflammatory nociceptive transmission; state-dependent actions via dorsal horn 5-HT(3) receptors in the anaesthetized rat. Pain 2000; 89:81–8
20. Svensson CI, Tran TK, Fitzsimmons B, Yaksh TL, Hua XY: Descending serotonergic facilitation of spinal ERK activation and pain behavior. FEBS Lett 2006; 580:6629–34
21. Dogrul A, Ossipov MH, Porreca F: Differential mediation of descending pain facilitation and inhibition by spinal 5HT-3 and 5HT-7 receptors. Brain Res 2009; 1280:52–9
22. Peters CM, Hayashida K, Ewan EE, Nakajima K, Obata H, Xu Q, Yaksh TL, Eisenach JC: Lack of analgesic efficacy of spinal ondansetron on thermal and mechanical hypersensitivity following spinal nerve ligation in the rat. Brain Res 2010; 1352:83–93
23. Okazaki R, Namba H, Yoshida H, Okai H, Miura T, Kawamura M: The antiallodynic effect of Neurotropin is mediated via activation of descending pain inhibitory systems in rats with spinal nerve ligation. Anesth Analg 2008; 107:1064–9
24. Fukushima T, Ohtsubo T, Tsuda M, Yanagawa Y, Hori Y: Facilitatory actions of serotonin type 3 receptors on GABAergic inhibitory synaptic transmission in the spinal superficial dorsal horn. J Neurophysiol 2009; 102:1459–71
25. Kawamata T, Omote K, Toriyabe M, Yamamoto H, Namiki A: The activation of 5-HT(3) receptors evokes GABA release in the spinal cord. Brain Res 2003; 978:250–5
26. Kim SH, Chung JM: An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992; 50:355–63
27. Yaksh TL, Rudy TA: Chronic catheterization of the spinal subarachnoid space. Physiol Behav 1976; 17:1031–6
28. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994; 53:55–63
29. Randall LO, Selitto JJ: A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 1957; 111:409–19
30. Brawek B, Löffler M, Weyerbrock A, Feuerstein TJ: Effects of gabapentin and pregabalin on K+-evoked 3H-GABA and 3H-glutamate release from human neocortical synaptosomes. Naunyn Schmiedebergs Arch Pharmacol 2009; 379:361–9
31. Eaton MJ, Plunkett JA, Karmally S, Martinez MA, Montanez K: Changes in GAD- and GABA- immunoreactivity in the spinal dorsal horn after peripheral nerve injury and promotion of recovery by lumbar transplant of immortalized serotonergic precursors. J Chem Neuroanat 1998; 16:57–72
32. Gwak YS, Hulsebosch CE: GABA and central neuropathic pain following spinal cord injury. Neuropharmacology 2011; 60:799–808
33. Liu J, Wolfe D, Hao S, Huang S, Glorioso JC, Mata M, Fink DJ: Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain. Mol Ther 2004; 10:57–66
34. Sonohata M, Furue H, Katafuchi T, Yasaka T, Doi A, Kumamoto E, Yoshimura M: Actions of noradrenaline on substantia gelatinosa neurones in the rat spinal cord revealed by in vivo patch recording. J Physiol 2004; 555:515–26
35. Takeda D, Nakatsuka T, Papke R, Gu JG: Modulation of inhibitory synaptic activity by a non-alpha4beta2, non-alpha7 subtype of nicotinic receptors in the substantia gelatinosa of adult rat spinal cord. Pain 2003; 101:13–23
36. Young T, Wittenauer S, Parker R, Vincler M: Peripheral nerve injury alters spinal nicotinic acetylcholine receptor pharmacology. Eur J Pharmacol 2008; 590:163–9
37. Hayashida KI, Bynum T, Vincler M, Eisenach JC: Inhibitory M2 muscarinic receptors are upregulated in both axotomized and intact small diameter dorsal root ganglion cells after peripheral nerve injury. Neuroscience 2006; 140:259–68
38. Bernardini N, Reeh PW, Sauer SK: Muscarinic M2 receptors inhibit heat-induced CGRP release from isolated rat skin. Neuroreport 2001; 12:2457–60
39. Dussor GO, Helesic G, Hargreaves KM, Flores CM: Cholinergic modulation of nociceptive responses in vivo and neuropeptide release in vitro at the level of the primary sensory neuron. Pain 2004; 107:22–32
40. Suzuki R, Rygh LJ, Dickenson AH: Bad news from the brain: Descending 5-HT pathways that control spinal pain processing. Trends Pharmacol Sci 2004; 25:613–7
41. Suzuki R, Morcuende S, Webber M, Hunt SP, Dickenson AH: Superficial NK1-expressing neurons control spinal excitability through activation of descending pathways. Nat Neurosci 2002; 5:1319–26
42. Zeitz KP, Guy N, Malmberg AB, Dirajlal S, Martin WJ, Sun L, Bonhaus DW, Stucky CL, Julius D, Basbaum AI: The 5-HT3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors. J Neurosci 2002; 22:1010–9
43. Chen Y, Oatway MA, Weaver LC: Blockade of the 5-HT3 receptor for days causes sustained relief from mechanical allodynia following spinal cord injury. J Neurosci Res 2009; 87:418–24
44. Oatway MA, Chen Y, Weaver LC: The 5-HT3 receptor facilitates at-level mechanical allodynia following spinal cord injury. Pain 2004; 110:259–68
45. Sasaki M, Ishizaki K, Obata H, Goto F: Effects of 5-HT2 and 5-HT3 receptors on the modulation of nociceptive transmission in rat spinal cord according to the formalin test. Eur J Pharmacol 2001; 424:45–52
46. Machu TK: Therapeutics of 5-HT3 receptor antagonists: Current uses and future directions. Pharmacol Ther 2011; 130:338–47
47. Simpson KH, Murphy P, Colthup PV, Whelan P: Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers. Psychopharmacology (Berl) 1992; 109:497–8
48. Hayashida K, DeGoes S, Curry R, Eisenach JC: Gabapentin activates spinal noradrenergic activity in rats and humans and reduces hypersensitivity after surgery. ANESTHESIOLOGY 2007; 106:557–62
This article has been cited 3 time(s).
Journal of Huazhong University of Science and Technology-Medical SciencesMelanocortin-4 receptor expression in the rostral ventromedial medulla involved in modulation of nociception in transgenic miceJournal of Huazhong University of Science and Technology-Medical Sciences
European Journal of PharmacologyMultiple roles of serotonin in pain control mechanisms -Implications of 5-HT7 and other 5-HT receptor typesEuropean Journal of Pharmacology
Progress in Neuro-Psychopharmacology & Biological PsychiatryThe antinociceptive effect of reversible monoamine oxidase-A inhibitors in a mouse neuropathic pain modelProgress in Neuro-Psychopharmacology & Biological Psychiatry
© 2012 American Society of Anesthesiologists, Inc.
Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.